Sijilmasa Ltd., Zhejiang Hisun Pharmaceutical Co., Ltd., and One Belt and One Road Group Limited signed a Memorandum of Understanding (MOU) in Beijing to build pharmaceutical plants in Morocco and the UAE. This partnership aims to foster sustainable growth in the pharmaceutical sector across the Middle East and Africa (MEA) by addressing rising healthcare demands, enhancing local production capabilities, and reducing reliance on imports.

The MEA region, with its growing population and increasing demand for healthcare, presents significant opportunities for pharmaceutical companies. Governments are prioritizing pharmaceutical sovereignty by encouraging local manufacturing and reducing dependency on external suppliers. This trend, accelerated by COVID-19, has led to policies promoting foreign investment and collaborations with local firms.

Despite challenges like low penetration of generic drugs and underdeveloped infrastructure, the region’s focus on self-reliance and supportive policies offers a fertile ground for companies with strong R & D, high production standards, and competitive pricing to succeed.

For more details, you can read these articles: article #1 – article #2